Company Filing History:
2 out of 559 
2 out of 3,539 
Years Active: 2020-2024
Title: Reuben Benjamin: Innovator in Cancer Treatment
Introduction
Reuben Benjamin is a notable inventor based in London, GB, recognized for his contributions to cancer treatment through innovative methods and compositions. With a total of two patents, his work focuses on harnessing the power of antigen-binding proteins to target specific cancer cells.
Latest Patents
Benjamin's latest patents include groundbreaking methods of treatments using antigen-binding proteins targeting CD56. These patents provide methods and compositions for treating cancers, such as multiple myeloma. They relate to anti-CD56 antibodies and chimeric antigen receptors (CARs) that specifically target human CD56. The CD56-specific CARs disclosed in his patents exhibit enhanced immune-activating properties, including significant anti-tumor activity.
Career Highlights
Throughout his career, Reuben Benjamin has worked with prestigious institutions, including Memorial Sloan Kettering Cancer Center and the National Institutes of Health, a component of the US Department of Health & Human Services. His work in these organizations has contributed to advancing cancer treatment methodologies.
Collaborations
Some of his notable coworkers include Michel Sadelain and Dimiter Stanchev Dimitrov, who have collaborated with him on various projects aimed at improving cancer therapies.
Conclusion
Reuben Benjamin's innovative work in targeting cancer cells through antigen-binding proteins has the potential to significantly impact cancer treatment. His contributions to the field are marked by his patents and collaborations with leading institutions and professionals.